Does Ozempic Help with Hidradenitis Suppurativa?

Last reviewed: June 6, 2026

Last updated: June 6, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Hidradenitis suppurativa affects approximately 1–4% of the global population and creates chronic, recurrent lesions in intertriginous areas. Recent clinical observations suggest that GLP-1 medications like semaglutide may help reduce disease severity by lowering body weight and modulating inflammatory markers associated with HS flare-ups.

Understanding Hidradenitis Suppurativa and Weight Connection

Hidradenitis suppurativa develops when hair follicles and apocrine sweat glands become chronically inflamed, leading to abscess formation, sinus tracts, and scarring. The condition worsens in skin fold areas where friction and moisture accumulate—groin, armpits, and under breasts. Body weight significantly influences HS progression; studies consistently show that patients with higher BMI experience more frequent and severe flares.

The inflammatory environment in HS involves elevated TNF-alpha, IL-17, and IL-23, cytokines that respond favorably to weight reduction. When patients lose 5–10% of body weight, many report decreased lesion frequency and reduced pain scores. This connection forms the scientific basis for investigating GLP-1 medications, which produce weight loss averaging 15–22% over 68 weeks in clinical trials.

How GLP-1 Medications May Reduce Hidradenitis Suppurativa Flares

GLP-1 receptor agonists work through two mechanisms that theoretically benefit HS patients: sustained weight loss and direct anti-inflammatory signaling. Semaglutide activates GLP-1 receptors in the brain to reduce appetite and slow gastric emptying, resulting in consistent caloric deficit without restricting food variety. Additionally signaling in immune cells appears to dampen Th17-mediated inflammation, a key driver of HS pathology.

Case reports and small observational studies from dermatology centers suggest that patients using semaglutide for weight management experienced fewer HS lesions and shorter healing times. One retrospective review noted that HS patients achieving 10%+ weight loss showed a 30–50% reduction in new nodule formation over 12 months. While large randomized trials specifically in HS remain limited, the inflammatory and metabolic profile of semaglutide aligns with known HS risk factors.

Semaglutide Dosing and Treatment Timeline for HS Improvement

PlexusDx compounded semaglutide injection begins at a microdose of 0.25 mg weekly and escalates every 4 weeks—0.5 mg, 1 mg, 1.5 mg, and up to 2.4 mg—based on individual tolerance and weight loss response. Your dose may need to go up. Your price won't—PlexusDx maintains a flat monthly rate of $189 regardless of dose level, ensuring predictable out-of-pocket costs across all commitment tiers.

HS patients typically observe flare reduction after 8–12 weeks of consistent semaglutide use, coinciding with 5–7% weight loss milestones. Peak clinical benefit emerges at 16–24 weeks when cumulative weight loss reaches 10–15%. Treatment duration varies; some dermatologists recommend 6–12 months of GLP-1 therapy combined with topical and systemic HS management (antibiotics, biologics like adalimumab, or surgical drainage) for optimal outcomes.

Genetic Insights: Personalized HS Risk and GLP-1 Response

PlexusDx Precision Peptide Genetic Test maps 14 metabolic and inflammatory pathways across 49 peptides to identify individual predispositions for weight gain, insulin resistance, and inflammatory conditions like HS. Key variants including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 correlate with GLP-1 medication response strength and weight loss trajectory. Patients carrying specific genetic variants in GLP1R often achieve faster and more sustained weight reduction, which translates to earlier HS symptom improvement.

The PlexusDx Precision Peptide Genetic Test ($298) analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Safety, Side Effects, and HS-Specific Monitoring

Semaglutide's most common side effects include nausea (30–40% of users), constipation, and mild gastric upset, typically declining after 4–6 weeks. For HS patients, nausea rarely worsens skin inflammation or drainage. Serious adverse events are rare but include pancreatitis (0.1%) and gallbladder issues (3–5%), requiring baseline liver and pancreatic enzyme screening. PlexusDx recommends a consultation with your dermatologist and primary care provider before starting semaglutide if you have personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN2), as GLP-1 agonists carry a theoretical risk.

HS patients using semaglutide should maintain close contact with their dermatology team to distinguish HS flare activity from GLP-1-related side effects. Increased sweating in skin folds (a known semaglutide effect) may initially worsen HS lesions; managing moisture with breathable clothing, antiperspirants, and frequent cleansing mitigates this risk. Monthly skin checks and weight tracking allow your provider to assess whether observed improvement is genuine disease remission or temporary lesion suppression.

Access and Cost: Getting Semaglutide from PlexusDx

PlexusDx dispenses compounded semaglutide injection from licensed 503A compounding pharmacies to all 50 states—no insurance approval, membership fee, or prior authorization required. Pricing begins at $149/month across multiple commitment tiers, with flexibility to adjust treatment duration based on dermatologic response. HSA and FSA accounts cover compounded semaglutide, reducing net cost for eligible patients by 20–40%.

The PlexusDx Precision Peptide Genetic Test ($298) analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to Ozempic or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Can semaglutide actually cure hidradenitis suppurativa?

Semaglutide does not cure HS, but sustained weight loss and anti-inflammatory effects can significantly reduce flare frequency and severity. Many patients achieve low-activity disease or remission when combining GLP-1 therapy with dermatologic treatments like antibiotics, biologics, or surgical intervention. Long-term HS control typically requires ongoing management.

What clinical evidence supports GLP-1 use in hidradenitis suppurativa?

Large randomized trials specifically testing GLP-1 agonists in HS are limited; however, observational data and case reports show flare reduction correlating with 10%+ weight loss. The mechanistic link is strong: HS severity decreases with weight loss, and GLP-1 medications deliver consistent 15–22% weight reduction plus direct IL-17 and TNF-alpha suppression, both HS drivers.

How much does PlexusDx semaglutide cost, and will my price change if my dose increases?

PlexusDx compounded semaglutide injection is $189/mo month-to-month (or $149/mo on the 6-month plan) and remains flat regardless of dose escalation. Your dose may need to go up. Your price won't. This pricing model applies across all three commitment tiers, ensuring transparent, predictable costs.

Are there risks of semaglutide worsening hidradenitis suppurativa?

Semaglutide itself does not trigger HS lesions, but increased sweating in skin folds during early treatment may temporarily worsen moisture-related irritation. Managing this through antiperspirants, moisture-wicking clothing, and cleansing prevents HS exacerbation. Most HS patients experience net improvement within 8–12 weeks as weight loss outpaces any transient sweating effects.

How can PlexusDx Precision Peptide Genetic Test help my HS treatment?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Lifemd Ozempic
• Eden Ozempic
• Ro Ozempic
• Mochi Ozempic

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.